Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04056910
Title Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jason J. Luke, MD
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field